BSE: 531592
GENPHARMASEC LIMITED
Operates as a pharmaceutical trader and distributor, with the Pharmaceuticals segment generating Rs 51.66 crore in FY26. A smaller Manufacturing & Processing line contributed Rs 3.76 crore, while a Laboratory Testing segment reported zero revenue. In July 2025, the company acquired a 70% stake in Derren Healthcare Private Limited, making it a subsidiary; Derren contributed a consolidated net loss of Rs 346.76 lakh in FY26. The company also runs a small Trading in Securities line. The cost shape is unusually thin, with materials at 2.0% of revenue, employees at 2.8%, and other operating expenses at 4.5%, fitting a low-margin distribution model rather than heavy manufacturing. Consolidated FY26 revenue stood at Rs 139.94 crore on an EBITDA margin of 3.13%, with net profit of Rs 0.56 crore. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceuticals, Manufacturing & Processing, Laboratory Testing, Trading in Securities. Thin-margin pharmaceutical trading and distribution with a recently loss-making healthcare subsidiary
Exhibit 1: Financial summary, FY24–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 30 | 34 | 140 |
| EBITDA (ex other income) | 0 | 0 | 1 |
| margin % | 0.2 | 0.2 | 0.9 |
| Owners' profit | (0) | 0 | 2 |
| EPS, as reported (₹) | 0.00 | 0.01 | 0.01 |
| ROE % · ROCE % | (0.3) · 1.0 | 1.9 · 3.3 | 0.9 · 2.4 |
| Debt / equity (x) | 0.05 | 0.05 | 0.50 |
| Cash from operations | (4) | 3 | (18) |
| Capex | 0 | (6) | (1) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 8 | 14 | 12 | 33 | 40 | 55 | 50 |
| Profit before tax | 1 | 1 | (0) | 1 | (1) | (1) | 2 | 0 |
| Net profit | 1 | 1 | (0) | 1 | (1) | (1) | 1 | (0) |
| EPS (₹) | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 |
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceuticals | 131 | 93.5 |
| Laboratory Testing | 1 | 0.7 |
| Manufacturing & Processing | 7 | 4.7 |
| Derren | 2 | 1.1 |
| Total, before eliminations | 140 | 100.0 |
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| REDINGTON LIMITED | 27,525 | 16.2 | 2.64 | 12.8 | 12.3 | 15.7 | 15.9 | 2.2 |
| MMTC LIMITED | 7,740 | 17.3 | 3.65 | 16.5 | 18.3 | 21.6 | (83.7) | 18426.5 |
| MSTC LIMITED | 3,896 | 16.6 | 4.31 | 11.3 | 24.2 | 31.8 | (13.9) | 86.5 |
| CREATIVE NEWTECH LIMITED | 1,653 | 25.4 | 4.27 | 19.0 | 18.1 | 21.0 | — | 5.2 |
| Pervasive Commodities Limited | 1,104 | — | 12.27 | — | (0.0) | (0.0) | — | 45.0 |
| SHIV AUM STEELS LIMITED | 736 | 64.8 | 6.09 | 47.0 | 6.0 | 6.9 | — | 4.9 |
| The Yamuna Syndicate Ltd | 736 | 8.1 | 0.57 | 185.3 | 4.0 | 0.3 | 4.8 | 6.2 |
| THE STATE TRADING CORPN | 602 | 0.9 | — | 51.0 | — | — | — | — |
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 16.3 | 13.9 | 70 of 130 | 47% |
| P/B | 0.8 | 0.9 | 68 of 150 | 54% |
| ROCE | 1.1 | 2.1 | 103 of 177 | 42% |
| ROE | 0.8 | 2.3 | 96 of 158 | 40% |
| Debt / Equity | 0.5 | 0.1 | 115 of 154 | 26% |
| EBITDA margin | 2.7 | 4.5 | 85 of 137 | 38% |
| Revenue growth | 312.8 | (8.6) | 11 of 135 | 93% |
| Profit growth | (114.3) | 0.6 | 125 of 157 | 21% |
| Market cap | 54 | 21 | 55 of 179 | 70% |
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 14 Oct 2026 · Dubai subsidiary renamed from DMCC to FZCO | business updates | low | — | — |
| 5 Oct 2026 · RTA cert: No physical share certificates received for demat in Q2 FY27 | compliance | minimal | — | — |
| 30 Sept 2026 · 34th AGM voting results: all 5 resolutions passed with over 99.99 percent approval | board shareholder meetings | low | — | — |
| 29 Sept 2026 · Genpharmasec submits 34th AGM proceedings | board shareholder meetings | low | — | — |
| 26 Sept 2026 · Trading window closed from Oct 1 ahead of Q2 results | compliance | minimal | — | — |
| 8 Sept 2026 · Newspaper publication of 34th AGM notice for Genpharmasec Limited | compliance | minimal | — | — |
| 7 Sept 2026 · Genpharmasec 34th Annual Report FY25-26 and AGM notice filed; AGM on Sept 29 | compliance | medium | — | — |
| 7 Sept 2026 · AGM on 29 September 2026 to consider accounts and director reappointment | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Book Closure for 34th AGM on 29 Sep 2026 | corporate actions | low | — | — |
| 2 Sept 2026 · Board approves 34th AGM, Annual Report, and re-appointment of Whole Time Director | board shareholder meetings | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.